![]() |
||||
|
|
||||
|
|
||||
ONCOLOGY: Ovarian Cancer Trial - Karenitecin(R)-BNP1350From: Hope Waltman (anonymous@obgyn.net)Sat, 9 Feb 2008 10:17:45 -0600 (CST)
BioNumerik Commences Global Phase III Ovarian Cancer Trial On Novel Anticancer Drug Candidate Known As Karenitecin(R) "BioNumerik Pharmaceuticals, Inc. announced treatment of the first patient in a global Phase III clinical trial of BioNumerik's anticancer drug candidate known as Karenitecin(R) in advanced ovarian cancer patients. BioNumerik is developing Karenitecin (also known as BNP1350) as an investigational new anti-tumor drug in the camptothecin class of chemotherapy drugs. Four Phase II clinical trials of intravenously administered Karenitecin have been completed in the U.S. in patients with advanced ovarian cancer, metastatic malignant melanoma, advanced non-small cell lung cancer, and primary brain tumors." http://www.medicalnewstoday.com/articles/96598.php Regards, Hope Waltman, Fibroid Forum and WH Forum Moderator http://www.hopeforfibroids.org http://www.doctorsinfoweb.com/doctors/whatsnew.htm http://www.obgyn.net/fibroid-resource-center/
|
|
Return to ![]()
Report TECHNICAL Problems ONLY to: webmaster@obgyn.net
Last Updated: Wed Dec 2 06:55:20 2009
Women's Insurance Checklist from Auto Insurance Quote
home | medical professionals | women | industry | forums | international